Stocks
IN8bio, Inc.INAB
NASDAQHealthcareBiotechnology$1.05
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for cancer. Its lead candidate, INB-100, is being evaluated in a Phase 1 trial for leukemia patients undergoing hematopoietic stem cell transplantation. Investors track IN8bio for its novel approach to allogeneic cell therapy and upcoming clinical data readouts.
52W Range: $0.88-$2.73
Congressional Interest in IN8bio, Inc. (INAB)
No congressional trades have been disclosed for IN8bio, Inc. (INAB) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading INAB?
No congressional trades found for this stock.